Medpace Holdings, Inc. (MEDP): A Bull Case Theory

We came across a bullish thesis on Medpace Holdings, Inc. on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc.'s share was trading at $455.68 as of July 24^th. MEDP’s trailing and forward P/E were 33.85 and 34.60, respectively according to Yahoo Finance.

Medpace Holdings is a leading full-service contract research organization (CRO) specializing in Phase I–IV clinical trials for small and mid-sized biotech, pharmaceutical, and medical device companies. These clients, often lacking the infrastructure to run trials in-house, rely on Medpace’s comprehensive suite of services, which include design, organization, and management of clinical studies.

By concentrating on this underserved client base, Medpace is positioned within the fastest-growing and most profitable segment of the CRO market. Over three decades, the company has built deep therapeutic expertise and a differentiated go-to-market approach, resulting in a competitive edge that has been developed entirely organically. This combination of focus, expertise, and scale allows Medpace to capture market share from larger peers that typically target big pharmaceutical clients.

Despite its strong positioning, Medpace’s stock has underperformed over the past year due to industry-wide concerns about biotech funding, which has constrained early-stage development activity. However, the company’s exposure to a resilient client base and its asset-light, high-margin model leave it well-equipped to navigate temporary market headwinds.

The current valuation provides an attractive entry point, as fundamentals remain intact and the long-term outlook for outsourced clinical development continues to strengthen amid rising complexity and regulatory requirements in drug development. Medpace’s unique strategy and consistent execution make it a compelling investment opportunity with the potential for significant upside as biotech funding conditions normalize and the company capitalizes on the accelerating demand for outsourced clinical trial services.

Previously, we covered a bullish thesis on Medpace Holdings, Inc. (MEDP) by Compound & Fire in May 2025, which highlighted its capital-light model, disciplined allocation, and growth in the CRO market. The company’s stock price has appreciated by approximately 49% since our coverage, as the thesis played out. Stock Analysis Compilation shares a similar view but emphasizes its edge in serving underserved biotech clients.

Medpace Holdings, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held MEDP at the end of the first quarter which was 42 in the previous quarter. While we acknowledge the potential of MEDP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None.